SK Bioscience Co

SK Bioscience Co EBITDA per Employee

The EBITDA per Employee of SK Bioscience Co (302440.KS) as of Oct 16, 2026 is -115.75 M KRW. In the previous year, EBITDA per Employee was -121.39 M KRW — a change of -4.65% (higher).

EBITDA per Employee

-115.75 MKRW

YoY

-4.65%

Last updated:

EBITDA per Employee of SK Bioscience Co is 2025 -115.75 M KRW. EBITDA per Employee of SK Bioscience Co was 2024 -121.39 M KRW. It decreases by -4.65% higher compared to the previous year.

The SK Bioscience Co EBITDA per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Employee
Date
EBITDA per Employee
Jan 1, 2018
3.15 M KRW
Jan 1, 2019
6.95 M KRW
Jan 1, 2020
37.87 M KRW
Jan 1, 2021
446.46 M KRW
Jan 1, 2022
111.41 M KRW
Jan 1, 2023
-5.76 M KRW
Jan 1, 2024
-121.39 M KRW
Jan 1, 2025
-115.75 M KRW
The SK Bioscience Co EBITDA per Employee history
YEAREBITDA per EmployeeYoY
-115.75 MKRW-4.65%
-121.39 MKRW+2,006.57%
-5.76 MKRW-105.17%
111.41 MKRW-75.05%
446.46 MKRW+1,078.82%
37.87 MKRW+444.88%
6.95 MKRW+120.94%
3.15 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SK Bioscience Co Stock analysis

What does SK Bioscience Co do? SK Bioscience Co Ltd is a South Korean biotechnology company headquartered in Seongnam, Gyeonggi-Do. The company went public on March 18, 2021, with its stock listed on the Korean Stock Exchange under the ticker 302440.KS. It operates within the health care sector, specifically in the biotechnology industry. SK Bioscience employs 1,067 people and focuses on the development and distribution of bio and vaccine products. The company distributes its products both domestically and internationally. While specific product names are mentioned in unverified sources, the company is known to be involved in the production of vaccines and infusion solutions. It also engages in technology export business, though detailed information about its technology or export markets is not provided. The company's website is https://www.skbioscience.co.kr/, where further information about its operations and products may be available. SK Bioscience does not disclose specific details about its product lines beyond the general categories of vaccines and infusion solutions, and it does not provide information on acquisitions, founding year, or key personnel. The company's activities are centered around biotechnology and healthcare, with a focus on vaccine development and distribution. Its market presence spans both domestic and international markets, though specific regions or countries are not specified. The company's financial data, including revenue and market capitalization, is not included in the provided information. SK Bioscience is a publicly traded company with a focus on biotechnology and healthcare innovation. SK Bioscience Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SK Bioscience Co stock

EBITDA per Employee of SK Bioscience Co is -115.75 M KRW in 2025.

EBITDA per Employee of SK Bioscience Co changed from -121.39 M KRW to -115.75 M KRW, representing a -4.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Employee SK Bioscience Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per employee measures operating cash earnings generated per employee, showing workforce productivity before depreciation and financing effects.

EBITDA per Employee's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA per Employee's SK Bioscience Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — SK Bioscience Co

All Key Metrics — SK Bioscience Co